Helix BioPharma Corp. Announces Fiscal First Quarter 2018

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
595
Helix BioPharma Corp. Announces Fiscal First Quarter 2018 Results

RICHMOND HILL, ONTARIO--(Marketwired - Dec. 13, 2017) - Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2018 ending October 31, 2017.

FINANCIAL REVIEW

The Company recorded a net loss and total comprehensive loss of $2,303,000 ($0.02 loss per common share) and $3,287,000 ($0.04 loss per common share) for the three-month periods ended October 31, 2017 and 2016, respectively.

Research and development

Research and development costs for the three-month periods ended October 31, 2017 and 2016 totalled $1,764,000 and $2,268,000, respectively.

The following table outlines research and development costs expensed for the Company's significant research and development projects for the three-month periods ended October 31:

2017 2016
L-DOS47 $ 1,482 $ 1,765
V-DOS47 113 149
Corporate research and development expenses 98 280
Trademark and patent related expenses 99 71
Depreciation expense 55 30
Polish government grant subsidy (V-DOS47) (83 ) (27 )
$ 1,764 $ 2,268

L-DOS47 research and development expenses for the three-month periods ended October 31, 2017 and 2016 totalled $1,482,000 and $1,765,000, respectively. L-DOS47 research and development expenditures relate primarily to the Company's LDOS002 European Phase I/II clinical study in Poland and the LDOS001 U.S. Phase I clinical study in the U.S in addition to some preliminary expenditures related to the Company's LDOS003 Phase II clinical study in Poland and the Ukraine that the Company plans to commence enrolment in early 2018.

V-DOS47 research and development expenses for the three-month periods ended October 31, 2017 and 2016 totalled $113,000 and $149,000, respectively. The Company's wholly owned subsidiary in Poland has a grant funding agreement with the PNCRD for research and development expenditures associated with V-DOS47. The Company's subsidiary received $83,000 and $27,000 in the three-month periods ended October 31, 2017 and 2016, respectively, from the PNCRD.

Corporate research and development expenses for the three-month periods ended October 31, 2017 and 2016 and totalled $98,000 and $280,000, respectively. The decrease in spending is the result of headcount reductions and external consulting contracts.

Trademark and patent related expenses for the three-month periods ended October 31, 2017 and 2016 totalled $99,000 and $71,000, respectively. The Company continues to ensure it adequately protects its intellectual property.

Operating, general and administration

Operating, general and administration expenses for the three-month periods ended October 31, 2017 and 2016 totalled $526,000 and $1,008,000, respectively.

The decrease in operating, general and administration expenses reflects various ongoing cost cutting initiatives.

LIQUIDITY AND CAPITAL RESOURCES

The Company reported a consolidated net loss and total comprehensive loss of $2,303,000 for the three-month period ended October 31, 2017 (October 31, 2016 - $3,287,000). As at October 31, 2017 the Company had working capital of $1,674,000, shareholders' equity of $2,129,000 and a deficit of $157,683,000. As at July 31, 2017 the Company had a working capital deficiency of $504,000, shareholders' deficiency of $17,000 and a deficit of $155,380,000.

The two private placements the Company closed during the three month-period ended October 31, 2017 for gross proceeds totalling $5,221,000 improved the Company's working capital positions. Nevertheless, the Company's cash reserves of $3,175,000 as at October 31, 2017 are insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months, nor are they sufficient to see the current or any planned research and development initiatives through to completion. Though the funds raised have assisted the Company in dealing with the working capital deficiency, additional funds are required to advance the various clinical and preclinical programs and pay for the Company's overhead costs. To the extent that the Company does not believe it has sufficient liquidity to meet its current obligations, management considers securing additional funds, primarily through the issuance of equity securities of the Company, to be critical for its development needs.

The Company's Consolidated Statement of Financial Position as at October 31, 2017 and July 31, 2017 is summarized below.

Consolidated Statement of Financial Position (thousand $)
31-Oct-17 31-Jul-17
Non current assets 455 487
Current assets:
Prepaids 56 173
Accounts receivable 409 630
Cash 3,175 897
3,640 1,700
Total assets 4,095 2,187
Shareholders' equity / (deficiency) 2,129 (17 )
Current liabilities:
Deferred government grant 83 44
Accrued liabilities 585 722
Accounts payable 1,298 1,438
1,966 2,204
Total liabilities & shareholders equity 4,095 2,187

The Company's Consolidated Statement of Net Loss and Comprehensive Loss and Consolidated Statement of Cash Flow for the three-month periods ended October 31, 2017 and 2016 are summarized below:

Consolidated Statements of Net Loss and Comprehensive Loss
(thousand $, except for per share data)
For the three-
months ended
Oct-31 Oct-31
2017 2016
Expenses:
Research and development 1,764 2,268
Operating, general, administration 526 1,008
Results from operating activities
before finance items (2,290 ) (3,276 )
Finance items (13 ) (11 )
Loss and total comprehensive loss (2,303 ) (3,287 )
Loss per share -$ 0.02 -$ 0.04
* Figures are for both basic and fully diluted
Consolidated Statements of Cash Flows
(thousand $)
For the three-
months ended
Oct-31 Oct-31
2017 2016
Cash provided by (used in):
Net loss and total comprehensive loss (2,303 ) (3,287 )
Items not involving cash:
Depreciation 61 36
Stock-based compensation 4 -
Foreign exchange loss (gain) 11 9
76 45
Changes in non-cash working capital 100 1,077
Operating activities (2,127 ) (2,165 )
Financing activities 4,445 1,030
Investing activities (29 ) (113 )
Exchange rate changes on cash (11 ) (9 )
Net increase (decrease) in cash 2,278 (1,257 )
Cash beginning of the period 897 3,654
Cash end of the period 3,175 2,397

The Company's condensed unaudited interim consolidated financial statements and management's discussion and analysis will be filed under the Company's profile on SEDAR at www.sedar.com , as well as on the Company's website.

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Forward-Looking Statements and Risks and Uncertainties

This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the Company's activities relating to DOS47, and other information in future periods.

Forward-looking statements include, without limitation, statements concerning (i) the Company's ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company's priority continuing to be L-DOS47; (iii) the Company's development programs for DOS47, L-DOS47, V-DOS47 and CAR-T; (iv) future expenditures, the insufficiency of the Company's current cash resources and the need for financing; and (v) future financing requirements and the seeking of additional funding. Forward-looking statements can further be identified by the use of forward-looking terminology such as "ongoing", "estimates", "expects", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", or "should" occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking statements are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release, including, but not limited to, the safety and efficacy of L-DOS47; that sufficient financing will be obtained in a timely manner to allow the Company to continue operations and implement its clinical trials in the manner and on the timelines anticipated; the timely provision of services and supplies or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; and the timely receipt of required regulatory approvals and strategic partner support.

The Company's actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation, the risk that the Company's assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company's research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in the Company's annual management's discussion and analysis for the year ended July 31, 2017 under the heading "Risks and Uncertainty" and Helix's Annual Information Form, in particular under the headings "Forward-looking Statements" and "Risk Factors", and other reports filed under the Company's profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

INVESTOR RELATIONS Helix BioPharma Corp. 9120 Leslie Street, Suite 205 Richmond Hill, Ontario, L4B 3J9 (905) 841-2300 ir@helixbiopharma.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 201

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Nvidia Faces SEC Probe Report and New Lawsuit Stakes

Updated Category News Views 40

Silicon Valley's favorite growth machine has stumbled into the sort of fog investors hate most: regulatory questions, leadership upheaval, and a stock-price reaction with no clean answer attached. Reports cited in the lawsuit update say the Securities and Exchange Commission has opened a civil probe into NVIDIA's investor disclosures following former CEO Jensen Huang's...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 131

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 22

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Teciem’s New CFO Puts Financial Discipline Behind Growth

Updated Category News Views 43

A finance chief moving continents is not decorative corporate wallpaper. Teciem’s decision to appoint Jesús Rueda Molins as chief financial officer says the company wants its next growth chapter run with more than product ambition and executive slogans. It wants somebody holding the purse strings who already knows the machinery, the customers and the people making the...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
SK hynix Faces Fresh DRAM Collusion Risk for Investors

Updated Category News Views 102

A Memory Market Win Can Turn Sour Fast Nothing rattles a chip story quite like the word collusion showing up beside a judge’s ruling. SK hynix had been riding a powerful memory-market narrative, but investors got a blunt reminder on November 15, 2026: a proposed U.S. class action accusing SK hynix, Samsung Electronics, and Micron of restricting DRAM supply to raise...

Continue Reading
Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 105

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 0

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading
The Hanover Survey Puts Small-Business Trust on Trial

Updated Category News Views 275

A dark storefront can apparently erase goodwill faster than plenty of owners want to admit. The Hanover Insurance Group's 2026 Small Business Pulse Report found that 60% of surveyed consumers would temporarily buy from a competitor if their preferred small business shut unexpectedly. More than half would start looking elsewhere within a week. That is not a cute...

Continue Reading

Top 5 Most Recently Viewed Articles

TCL's Innovative Initiatives: Sustainability and Creativity Unite

Updated Category News Views 304

TCL's Commitment to Innovation and Sustainability At IFA 2024, TCL, a prominent global technology brand, showcased its unwavering dedication to innovation and sustainability. This year marks TCL's 14th consecutive appearance at the event, where the company highlighted two key initiatives: TCLGreen and TCLArt. These initiatives have attracted considerable attention as they...

Continue Reading
Western Metallica Closes Private Placement to Boost Copper Projects

Updated Category News Views 209

Western Metallica's Successful Private Placement Financing Western Metallica Resources Corp. (TSXV: WMS) has successfully completed its non-brokered private placement financing. This strategic decision allowed the company to issue a significant number of units at an appealing price point. By offering 10,833,345 units at $0.03 each, Western Metallica raised gross proceeds...

Continue Reading
Astrion's New Leadership Team Set to Drive Future Innovations

Updated Category News Views 250

Astrion Unveils Dynamic Executive Leadership Team Astrion, a leader in providing advanced engineering services and mission support to government sectors, has recently announced an exciting new executive leadership team. This strategic move aligns with their ongoing mission to deliver innovative solutions following the acquisition of Axient. With industry veteran Dave...

Continue Reading
Keyera Corp. Schedules Conference Call for Q3 2024 Results

Updated Category News Views 119

Keyera Corp. Schedules 2024 Q3 Results Conference Call Keyera Corp. has announced its timeline for the release of third-quarter results. Investors and interested parties are encouraged to take note of the important dates surrounding this announcement. When to Expect the Financial Results The financial results are set to be released before the market opens on November 14,...

Continue Reading
Netflix Partners with WWE to Revitalize Global Wrestling Fanbase

Updated Category News Views 411

Netflix and WWE Join Forces for a Live Streaming Revolution In an exciting new venture, Netflix has entered the world of live programming by teaming up with World Wrestling Entertainment (WWE) to stream its flagship show, "Raw." This collaboration marks a significant shift in how wrestling fans will experience their favorite matches, bringing the thrill of live...

Continue Reading